

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10511537	
	Filing Date		2004-10-15	
	First Named Inventor	Hanson		
	Art Unit	1624		
	Examiner Name	Mark L. Berch		
Attorney Docket Number		100647-1P US		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5716967		1998-02-10	Kleinman	
	2	5976823		1999-11-02	Wu	
	3	6046019		2000-04-04	Gourmeniouk et al.	
	4	6294541		2001-09-25	Cavalla et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20040022871		2004-02-05	Mainnemare	
	2	20040029871		2004-02-12	Kettle et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

3	20070032468	2007-02-08	Kettle et al.	
---	-------------	------------	---------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1013676	CN		1991-08-28	Euroceltique S.A.		<input checked="" type="checkbox"/>
	2	9917773	WO	A1	1999-04-15	Smithkline Beecham Corporation		<input type="checkbox"/>
	3	0051598	WO	A1	2000-09-08	Smithkline Beecham Corporation		<input type="checkbox"/>
	4	0208237	WO	A2	2002-01-31	Lyles, Mark B.		<input type="checkbox"/>
	5	02090575	WO	A1	2002-11-14	AstraZeneca AB		<input type="checkbox"/>
	6	2005037835	WO	A1	2005-04-28	AstraZeneca AB		<input type="checkbox"/>
	7	2005077950	WO	A2	2005-08-25	Smithkline Beecham Corporation		<input type="checkbox"/>
	8	2006045564	WO	A1	2006-05-04	Smithkline Beecham Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AARON, S D et al., "Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease," Am J Respir Crit Care Med., 2001, pgs. 349-355, vol. 163	<input type="checkbox"/>
	2	AKBIYIK et al., "In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil," Eur. J. Clin. Pharmacol., 2001, Vol. 57, pgs. 631-636	<input type="checkbox"/>
	3	BALDUS, S. et al., "Myeloperoxidase Serum Levels Predict Risk in Patients with Acute Coronary Syndromes," Circulation, 2003, pgs. 1440-1445, vol. 108	<input type="checkbox"/>
	4	BERLOW et al., "The Effect of Dapsone in Steroid-Dependent Asthma," 1991, J. Allergy Clin. Immunol., 1991, Vol. 87 (3), pgs. 710-715	<input type="checkbox"/>
	5	BOZEMAN et al., "Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone," Biochemical Pharmacology, 1992, Vol. 44, No. 3, pgs. 553-563	<input type="checkbox"/>
	6	BRENNAN, M. et al., "Prognostic Value of Myeloperoxidase in Patients with Chest Pain," N Engl J Med., 2003, pgs 1595-1604, vol. 349, no. 17	<input type="checkbox"/>
	7	CHOI, D-K et al., "Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice," J. Neurosci., 2005, pgs. 6594-6600, vol. 25, no. 28	<input type="checkbox"/>
	8	CROOKS, S W et al., "Bronchial Inflammation in Acute Bacterial Exacerbations of Chronic Bronchitis: the Role of Leukotriene B4," European Respiratory Journal, 2000, pgs. 274-280, vol. 15, no. 2	<input type="checkbox"/>
	9	CUZNER, M L et al., "Plasminogen Activators and Matrix Metalloproteases, Mediators of Extracellular Proteolysis in Inflammatory Demyelination of the Central Nervous System," Journal of Neuroimmunology, 1999, pgs. 1-14, vol. 94, no. 1-2	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

10	DALLEGRI et al., Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation," Arzneimittel-Forschung/Drug Research, 1995, Vol. 45(II), No. 10, pgs. 1114-1117	<input type="checkbox"/>
11	DAUGHERTY, A. et al., "Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerotic Lesions," J Clin Invest., 1994, pgs. 437-444, vol. 94, no. 1	<input type="checkbox"/>
12	FIORINI, G. et al., "Serum ECP and MPO are Increased During Exacerbations of Chronic Bronchitis with Airway Obstruction," Biomedicine & Pharmacotherapy, 2000, pgs. 274-278, vol. 54	<input type="checkbox"/>
13	GREEN, P S et al., "Neuronal Expression of Myeloperoxidase is Increased in Alzheimer's Disease," Journal of Neurochemistry, 2004, pgs. 724-733, vol. 90, no. 3	<input type="checkbox"/>
14	GRISHAM et al., "Assessment of Leukocyte involvement during Ischemia and Reperfusion of Intestine," Am. J. Physiol., 1986, Vol. 251, pgs. 729-742	<input type="checkbox"/>
15	HAMPTON, M B, et al., "Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing," Blood, 1998, pgs. 3007-3017, vol. 92, no. 9	<input type="checkbox"/>
16	HOPE et al., "Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase," Protein Expression and Purification, 2000, Vol. 18, pgs. 269-276	<input type="checkbox"/>
17	KETTLE et al., "Assays for the Chlorination Activity of Myeloperoxidase," Biophys, 1992, Vol. 296, pgs. 502-512	<input type="checkbox"/>
18	KETTLE et al., "Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs," Biochemical Pharmacology, 1991, Vol. 41, No. 10, pgs. 1485-1492	<input type="checkbox"/>
19	KETTLE et al., "Superoxide is an Antagonist of Anti-Inflammatory Drugs that Inhibit Hypochlorous Acid Production by Myeloperoxidase," Biochemical Pharmacology, 1993, Vol. 45, No. 10, pgs. 2003-2010	<input type="checkbox"/>
20	Khimicheskaya encyclopedia, ed. by Knunyants I.L., "Sovetskaya encyclopedia", 1990, V. 2, pg. 1083	<input checked="" type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/10/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

21	KUTTER, D. et al., "Consequences of Total and Subtotal Myeloperoxidase Deficiency: Risk or Benefit?," Acta Haematol, 2000, pgs. 10-15, vol. 104, no. 1	<input type="checkbox"/>
22	LECKIE et al., "Novel Therapy for COPD," Exp. Opin. Invest. Drugs, 2000, Vol. 9(1), pgs. 3-23	<input type="checkbox"/>
23	MARTIN et al., "Reduction of Neutrophil-mediated injury to pulmonary endothelial cells by Dapsone 1-3", Am. Rev. Respir Dis., 1985, Vol. 131, pgs. 544-547	<input type="checkbox"/>
24	NAGRA, R M, et al., "Immunohistochemical and Genetic Evidence of Myeloperoxidase Involvement in Multiple Sclerosis," Journal of Neuroimmunology, 1997, pgs 97-107, vol 78, no. 1-2	<input type="checkbox"/>
25	NOCKER et al., "Interleukin-8 in Airway Inflammation in Patients with Chronic Asthma and Chronic Obstructive Pulmonary Disease," Int. Arch Allergy Immunol., 1996, Vol. 109, pgs. 183-191	<input type="checkbox"/>
26	OTTONELLO et al., "Sulphonamides as Anti-Inflammatory Agents: Old Drugs for New Therapeutic Strategies in Neutrophilic Inflammation," Clinical Science, 1995, Vol. 88, pgs. 331-336	<input type="checkbox"/>
27	SUGIYAMA, S. et al., "Macrophage Myeloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes," Am J Pathol, 2001, pgs. 879-891, vol. 158, no. 3	<input type="checkbox"/>
28	SUZUKI et al., "Assay method for myeloperoxidase in human polymorphonuclear leukocytes," Analytical Biochemistry, 1983, Vol. 132, pgs. 345-352	<input type="checkbox"/>
29	VAN ZYL et al., "Interaction of methylxanthines with myeloperoxidase. An anti-inflammatory mechanism," Intl J. of Biochem, 1992, Vol. 24(6), pgs. 929-935	<input type="checkbox"/>
30	ZHANG, R. et al., "Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease," Jama, 2001, pgs. 2136-2142, vol. 286, no. 17	<input type="checkbox"/>
31	STN Intl. CAPLUS Accession No. 1968:434597, Doc No. 69:34597, Dietz et al., "The hypnotic properties of 8-ethylthio-6-thiotheophylline sodium" & Toxicology and Applied Pharm., 1968, Vol. 12, pgs. 202-6	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

32	STN Intl, CAPLUS Accession No. 1966:420839, Doc No. 65:20839, Dietz et al., "The synthesis and pharmacologic evaluation of a series of 8-alkylthio-thiated theophyllines" & J. of Med Chem., 1966, Vol. 9(4), pgs. 500-506	<input type="checkbox"/>
33	STN Intl, CAPLUS Accession No. 1966:35888, Doc No. 64:35888, Dietz et al., "Synthesis of some 8-alkylthio-2-thiotheophyllines and 8-alkylthio-6-thiotheophyllines" & J. of Med Chem., 1966, Vol. 9(1), pg. 160	<input type="checkbox"/>
34	STN Intl CAPLUS Accession No. 1974:82889, No. 80:82889, Reichman, Uri et al., "Tautomerism, ionization and methylation of 2(methylthio)- and 2,8-bis(methyl-thio)hypoxanthines" & J. of the Chem. Soc., Perkin Transactions 1: Organic & BioOrganic Chem, 1972-1999, (22), 2647-55, 1973	<input type="checkbox"/>
35	STN Intl, File CAPLUS Accession No. 1984:630460, Doc No. 101:230460, Talukdar, P.B. et al., "Studies on ring-fused mesoionic thiazolo(3,2-a) imidazo(4,5-d)pyrimidine derivatives," & Indian J. of Chem, Section B: Organic Chem. Including Medicinal Chem, 23B(4), pgs. 316-320, 1984	<input type="checkbox"/>
36	STN Intl, file Registry, "2H-Purin-2-one, 1,3,6,7-tetrahydro-8-(methylthio)-6-thioxo-(9CI)" Reg No. 500336-85-6	<input type="checkbox"/>
37	STN Intl, file Registry, "2-H-Purin-2-one, 1,3,6,7-tetrahydro-8-(propylthio)-6-thioxo-, sodium salt (9CI)" Reg No. 5784-48-5	<input type="checkbox"/>
38	STN Intl, file Registry, "1H-Purine-2,6-dithione, 3,7-dihydro-1,3-dimethyl-8-(methylthio)-, sodium salt (9CI)" Reg No. 5779-07-7	<input type="checkbox"/>
39	STN Intl, file Registry, "2H-Purin-2-one, 8-[(1-ethylbutyl)thio]-1,3,6,7-tetrahydro-1,3-dimethyl-6-thioxo-, sodium salt (9CI)", Reg No. 5779-06-6	<input type="checkbox"/>
40	STN printout for Registry No. 582-33-2: 3-Aminobenzoic acid ethyl ester	<input type="checkbox"/>
41	CAPLUS 1986:626214, English abstract for CN 1013676	<input type="checkbox"/>
42	Non-final Office Action issued for U.S. patent application No. 10/476,999 on October 31, 2005 (10/476,999 issued September 19, 2006 as U.S. patent no. 7,108,997, which was cited on Form SB08a submitted July 23, 2007)	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10511537
Filing Date	2004-10-15
First Named Inventor	Hanson
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	100647-1P US

43	Advisory Action issued for 10/275,824 on May 22, 2007 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
44	Copy of final Office Action issued for 10/275,824 on February 8, 2007 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
45	Non-final Office Action issued for 10/275,824 on June 19, 2006 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
46	Advisory Action issued for 10/275,824 on March 15, 2006 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
47	Final Office Action issued for 10/275,824 on November 30, 2005 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
48	Non-final Office Action issued for 10/275, 824 on June 17, 2005 (10/275,824, which is now abandoned, published as U.S. publication No. 2004-0029871, which is cited hereinabove)	<input type="checkbox"/>
49	U.S. Application Serial No. 11/756,967, Attorney Docket No. 102288-2 US, filed June 1, 2007	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/18/2007)